Dexmedetomidine Effects on Brain Tissue Oxygenation Measured by Frequency Domain Near Infrared Spectroscopy
The Internet Journal of Neuromonitoring · 2007
DOI: 10.5580/1e28 ↗At a glance
Journal article in The Internet Journal of Neuromonitoring, 2007.
Abstract (original language)
Dexmedetomidine (DEX) is a selective alpha2-adrenergic agonist that produces cerebral vasoconstriction. We used frequency domain near infrared spectroscopy (FD-NIRS) to study brain oxygenation during DEX intravenous bolus injection. Oxyhemoglobin (OHb), deoxyhemoglobin (HHb), brain oxygen saturation (SO2) and total hemoglobin (tHb) were acquired on the frontal right and left side in 4 neurosurgery patients without cerebral pathology. Measurements were performed using a portable brain oxymeter, Oxiplex TS (ISS, Champaign, IL). Dexmedetomidine 0.2 mcg/kg was given to attenuate hypertension during the initial stages of desflurane anesthesia. During DEX administration, regional cerebral OHb decreased from 17.7 ± 6.9 Mol/L to 16.1 ± 6.3 Mol/L (p < 0.05) and SO2 from 61 ± 12 % to 58 ± 12 % (p < 0.05). HHb did not change from 10.5 ± 2.8 Mol to 10.5 ± 2.7 Mol/L. Recovery of brain oxygenation to pre-DEX levels occurred within 5 minutes. After administration of DEX, a small but consistent decrease in OHb was observed, probably mediated by a local vasoconstrictor effect. Brain oxygenation decreased transiently with DEX treatment without an increase in HHb production.
Cite
APA
(2007). Dexmedetomidine Effects on Brain Tissue Oxygenation Measured by Frequency Domain Near Infrared Spectroscopy. The Internet Journal of Neuromonitoring. https://doi.org/10.5580/1e28
Vancouver
Dexmedetomidine Effects on Brain Tissue Oxygenation Measured by Frequency Domain Near Infrared Spectroscopy. The Internet Journal of Neuromonitoring. 2007. doi:10.5580/1e28
BibTeX
@article{euvimed2007,
title = {Dexmedetomidine Effects on Brain Tissue Oxygenation Measured by Frequency Domain Near Infrared Spectroscopy},
journal = {The Internet Journal of Neuromonitoring},
year = {2007},
doi = {10.5580/1e28}
}
EUVIMED